Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 2/20 | 0.67 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.67 |
| ▸ | HTR6 | P50406 | 5/20 | 0.60 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495922 | 0.92 | KCNN4 (0.64) | KCNN4KCNA3HTR6MMP2MEN1 | |
| SCHEMBL2705507 | 0.86 | KMT2A (0.68) | KCNN4KCNA3HTR6MMP2MEN1 | |
| SCHEMBL12662775 | 0.86 | MEN1 (0.49) | KCNN4KCNA3HTR6MEN1KMT2A | |
| SCHEMBL28665779 | 0.85 | KCNA3 (0.89) | KCNN4KCNA3HTR6MMP2GAA | |
| SCHEMBL12626577 | 0.85 | NPC1 (0.58) | KCNN4KCNA3HTR6MMP2HTR1A | |
| SCHEMBL2514013 | 0.82 | KCNN4 (0.55) | KCNN4KCNA3HTR6MMP2MEN1 | |
| SCHEMBL12679669 | 0.82 | KCNN4 (0.55) | KCNN4KCNA3HTR6MMP2MEN1 | |
| SCHEMBL2514016 | 0.82 | KCNN4 (0.55) | KCNN4KCNA3HTR6MMP2MEN1 | |
| SCHEMBL16794469 | 0.81 | HTR6 (0.50) | KCNN4KCNA3HTR6MMP2MEN1 | |
| SCHEMBL29676616 | 0.81 | HTR6 (0.50) | KCNN4KCNA3HTR6MMP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110963966-A | Method for preparing 2, 3-dihydroquinoline-4 (1H) -ketone derivative | 中国科学院大连化学物理研究所 | 2020-04-07 | — | — | CN | disclosed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | GALLEY GUIDO (DE) | 2012-03-22 | — | — | US | disclosed |
| EP-1981499-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007085558-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085558-A1 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-1427706-B1 | SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORP (US) | 2007-05-30 | — | — | EP | disclosed |
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | disclosed |
| US-7211597-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2007-05-01 | — | — | US | disclosed |
| EP-1019380-A2 | TRICYCLIC 3-OXO-PROPANENITRILE COMPOUNDS | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999016753-A2 | TRICYCLIC 3-OXO-PROPANENITRILE COMPOUNDS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071506-A1 | METHODS FOR TREATING CNS DISORDERS WITH BICYCLO-SUBSTITUTED 2-IMIDAZOLINE AND 2-IMIDAZOLES | CRY1, PER2, GPR119 | KCNN4 1239/4885KCNA3 1246/4885HTR6 116/4885 |
| US-20070197620-A1 | Methods for treating CNS disorders with bicyclo-substituted 2-imidazoline and 2-imidazoles | CRY1, PER2, GPR119 | KCNN4 1257/4885KCNA3 1270/4885HTR6 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.